GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
G

GNT Biotech & Medicals 7427.TWO · TWD

Health Care · Taipei Exchange · 🇹🇼 Taiwan

Compare

60.00

+3.09%

Close of 9 Nov 2026, in TWD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About GNT Biotech & Medicals

Its shares trade on Taipei Exchange under the ticker 7427.TWO. It has been listed since 8 July 2021. In the fiscal year to 31 December 2025, it reported revenue of TWD 1.2m and a net loss of TWD 97.5m. At that date it held total assets of TWD 526.8m and shareholders' equity of TWD 503.0m.

Great Novel Therapeutics Biotech & Medicals Corp. engages in the research and development of cancer medical treatment. The company is headquartered in Taipei City, Taipei. The company went IPO on 2021-07-08. The main product is the oral anti-cancer targeted new drug TM/Kepida, which is mainly used for the treatment of relapsed and refractory peripheral T-cell lymphoma (R/R PTCL) and ER+/Her-2-advanced breast cancer (ER+/Her-2-BC). The firm is also engaged in the research and development of tumor immunotherapies. The products include GNTbm-CC-01 and GNTbm-CC-02, which are tumor microenvironment regulator new drug combinations, as well as GNTbm-38, which is surface immunomodulator.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
8 Jul 2021
Employees
15

Leadership

Pay as last reported

  • Mr. Jianan ChenChairman of the Board, General Manager, since 2013
  • Ms. Yuexiu ZhaoDeputy General Manager
  • Zhenjia TangHead of Finance & Accounting
  • Peijing XuCorporate Governance Officer
  • Mr. Mingyi HuangDirector
  • Mr. Zhongyang HuangDirector
  • Mr. Gary TsengDirector
  • Mr. Zhongyi ChenIndependent Director
  • Ms. Ming-Hsuan LiIndependent Director
  • Mr. Shangpu XiaIndependent Director
  • Mr. Honghui ZhengIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • GNTbm-CC-01 and GNTbm-CC-02 target tumor microenvironment regulators for cancer treatment.
  • TM/Kepida addresses relapsed and refractory peripheral T-cell lymphoma and breast cancer.
  • GNTbm-38 functions as a surface immunomodulator for cancer therapy.

Weaknesses

  • 15 full-time employees limit research and development capacity.
  • The company's IPO on 8 July 2021 indicates limited market experience.
  • Taipei City headquarters may restrict global expansion opportunities.

Opportunities

  • The global cancer treatment market offers significant growth potential.
  • ER+/Her-2-advanced breast cancer treatment has high demand.
  • Tumor immunotherapy research aligns with emerging medical trends.

Threats

  • Relapsed and refractory cancer treatments face intense competition.
  • Regulatory approvals for new drugs may delay market entry.
  • Limited employee count could hinder rapid response to market changes.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.